Navigation Links
Rigel Announces Second Quarter 2009 Financial Results
Date:8/4/2009

SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2009.

For the second quarter of 2009, Rigel reported a net loss of $29.9 million, or $0.81 per share, compared to a net loss of $34.0 million, or $0.93 per share, in the second quarter of 2008. Weighted average shares outstanding for the second quarters of 2009 and 2008 were 36.7 million and 36.5 million, respectively.

Rigel reported total operating expenses of $30.0 million in the second quarter of 2009, compared to $35.3 million in the second quarter of 2008. The decrease in operating expenses was primarily due to decreases in stock-based compensation expense and cost savings as a result of the restructuring implemented in the first quarter of 2009. Stock-based compensation expenses decreased from $5.9 million in the second quarter of 2008 to $3.9 million in the second quarter of 2009, primarily due to a higher valuation of options granted in the first quarter of 2008 and the full expense recognition of the majority of those options by the end of 2008.

For the six months ended June 30, 2009, Rigel reported a net loss of $59.8 million, or $1.63 per share, compared to a net loss in the first six months of 2008 of $61.3 million, or $1.73 per share.

As of June 30, 2009, Rigel had cash, cash equivalents and available for sale securities of $79.9 million compared to $134.5 million as of December 31, 2008. The Company believes that its existing capital resources are sufficient to maintain its current development priorities through at least the end of the second quarter of 2010.

"With the results from our Phase 2b clinical trials for R788 now in hand, our focus is to secure a collaboration partner for R788," said James M. Gower, chairman and chief executive officer of Rigel. "As I have previously mentioned, our objective with R788 in rheumatoid arthritis is to position the product after methotrexate and before biological therapies are used. We have shown excellent results in TASKi1 and TASKi2 studies, and we believe that patient population represents the larger market opportunity for this product. We will also be preparing for the Phase 3 clinical trials for R788 with a collaboration partner," he added.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the sufficiency of Rigel's cash resources, Rigel's plans to secure a collaboration partner for R788, and Rigel's plans to pursue further clinical development of R788, and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "focus," "will," "scheduled," "our objective" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials, potential problems that may arise in the clinical testing and approval process, Rigel's expected dependence upon reaching an agreement with a collaboration partner for R788 and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-Q for the three months ended March 31, 2009. Rigel does not undertake any obligation to update forward-looking statements.

    Contact: Ryan D. Maynard
    Phone: 650.624.1284
    Email: invrel@rigel.com

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777
    Email: susan@alchemyemail.com

                           STATEMENTS OF OPERATIONS
                   (in thousands, except per share amounts)


                                       Three Months        Six Months
                                      Ended June 30,      Ended June 30,
                                      2009      2008      2009      2008
                                      ----      ----      ----      ----
                                       (unaudited)         (unaudited)
    Revenues:
      Contract revenues                  $-        $-        $-        $-

    Operating expenses:
      Research and development
       (see Note A)                  24,948    28,416    49,486    50,036
      General and administrative
       (see Note A)                   5,050     6,861     9,653    13,986
      Restructuring charges
       (see Note A)                       -         -     1,141         -
                                     ------    ------    ------    ------
          Total operating
           expenses                  29,998    35,277    60,280    64,022
                                     ------    ------    ------    ------
    Loss from operations            (29,998)  (35,277)  (60,280)  (64,022)
    Interest income, net                 90     1,248       384     2,731
                                      -----     -----     -----     -----
    Loss before income taxes        (29,908)  (34,029)  (59,896)  (61,291)
    Income tax benefit                   27         -        93         -
                                     ------    ------    ------    ------
    Net loss                       $(29,881) $(34,029) $(59,803) $(61,291)
                                   ========  ========  ========  ========
    Net loss per share, basic and
     diluted                         $(0.81)   $(0.93)   $(1.63)   $(1.73)
                                     ======    ======    ======    ======
    Weighted average shares
     used in computing
     net loss per share, basic
     and diluted                     36,704    36,505    36,701    35,461
                                     ======    ======    ======    ======



    --------------------------
    Note A

    Stock-based compensation
     expense included in:
      Research and development       $2,528    $3,102    $3,953    $6,194
      General and
       administrative                 1,331     2,817     2,050     5,571
      Restructuring charges               -         -       122         -
                                      -----     -----     -----     -----
                                     $3,859    $5,919    $6,125   $11,765
                                     ======    ======    ======   =======



                    SUMMARY BALANCE SHEET DATA
                           (in thousands)

                                      June   December
                                       30,      31,
                                      2009    2008(1)
                                      ----    -------
                                  (unaudited)
      Cash, cash equivalents
       and available
       for sale securities          $79,945  $134,477
      Total assets                   88,223   143,858
      Stockholders' equity           51,555   104,165


    (1) Derived from audited financial statements


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
4. Rigel Announces Offering of 4,000,000 Shares of Common Stock
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
8. Rigel Announces First Quarter 2008 Financial Results
9. Rigel to Present at Collins Stewart Growth Conference
10. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
11. Rigel to Webcast Investor Update on October 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology: